{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T05:58:54Z","timestamp":1781675934540,"version":"3.54.5"},"reference-count":19,"publisher":"Norwegian Medical Association","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tidsskr Nor Legeforen","Tidsskriftet"],"published-print":{"date-parts":[[2009,11,19]]},"DOI":"10.4045\/tidsskr.09.0471","type":"journal-article","created":{"date-parts":[[2009,11,25]],"date-time":"2009-11-25T09:36:09Z","timestamp":1259141769000},"page":"2364-6","source":"Crossref","is-referenced-by-count":0,"title":["Interaksjoner med metadon og buprenorfin"],"prefix":"10.4045","volume":"129","author":[{"given":"Eirin","family":"Bakke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liliana","family":"Bachs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2479","reference":[{"key":"ref=1","unstructured":"Spigset O, Molden E. Cytokrom P-450 3A4 - kroppens viktigste arena for legemiddelinteraksjoner. Tidsskr Nor L\u00e6geforen 2008; 128: 2832-5."},{"key":"ref=2","doi-asserted-by":"crossref","unstructured":"Ferrari A, Coccia CP, Bertolini A et al. Methadone \u2013 metabolism, pharmacokinetics and interactions.Pharmacol Res 2004; 50: 551\u20139.","DOI":"10.1016\/j.phrs.2004.05.002"},{"key":"ref=3","doi-asserted-by":"crossref","unstructured":"Bruce RD, McCance-Katz E, Kharasch ED et al. Pharmacokinetic interactions between buprenorphine and antiretroviral medications. Clin Infect Dis 2006; 43 (suppl 4): 216\u201323.","DOI":"10.1086\/508186"},{"key":"ref=4","doi-asserted-by":"crossref","unstructured":"Elkader A, Sproule B. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin Pharmacokinet 2005; 44: 661\u201380.","DOI":"10.2165\/00003088-200544070-00001"},{"key":"ref=5","doi-asserted-by":"crossref","unstructured":"Begre S, von BU, Ladewig D et al. Paroxetine increases steady-state concentrations of (R)-methadone in CYP2D6 extensive but not poor metabolizers. J Clin Psychopharmacol 2002; 22: 211\u20135.","DOI":"10.1097\/00004714-200204000-00017"},{"key":"ref=6","doi-asserted-by":"crossref","unstructured":"Hamilton SP, Nunes EV, Janal M et al. The effect of sertraline on methadone plasma levels in methadone-maintenance patients. Am J Addict 2000; 9: 63\u20139.","DOI":"10.1080\/10550490050172236"},{"key":"ref=7","doi-asserted-by":"crossref","unstructured":"Iribarne C, Picart D, Dreano Y et al. In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine. Fundam Clin Pharmacol 1998; 12: 194\u20139.","DOI":"10.1111\/j.1472-8206.1998.tb00941.x"},{"key":"ref=8","doi-asserted-by":"crossref","unstructured":"Gillman PK. Monoamine oxidase inhibitors, opioid analgesics and serotonin toxicity. Br J Anaesth 2005; 95: 434\u201341.","DOI":"10.1093\/bja\/aei210"},{"key":"ref=9","doi-asserted-by":"crossref","unstructured":"Krantz MJ, Kutinsky IB, Robertson AD et al. Dose-related effects of methadone on QT prolongation in\u00a0a series of patients with torsade de pointes. Pharmacotherapy 2003; 23: 802\u20135.","DOI":"10.1592\/phco.23.6.802.32186"},{"key":"ref=10","doi-asserted-by":"crossref","unstructured":"Liu SJ, Wang RI. Case report of barbiturate-induced enhancement of methadone metabolism and withdrawal syndrome. Am J Psychiatry 1984; 141: 1287\u20138.","DOI":"10.1176\/ajp.141.10.1287"},{"key":"ref=11","unstructured":"Saxon AJ, Whittaker S, Hawker CS. Valproic acid, unlike other anticonvulsants, has no effect on methadone metabolism: two cases. J Clin Psychiatry 1989; 50: 228\u20139."},{"key":"ref=12","doi-asserted-by":"crossref","unstructured":"Tong TG, Pond SM, Kreek MJ et al. Phenytoin-induced methadone withdrawal. Ann Intern Med 1981; 94: 349\u201351.","DOI":"10.7326\/0003-4819-94-3-349"},{"key":"ref=13","doi-asserted-by":"crossref","unstructured":"Herrlin K, Segerdahl M, Gustafsson LL et al. Methadone, ciprofloxacin, and adverse drug reactions. Lancet 2000; 356: 2069\u201370.","DOI":"10.1016\/S0140-6736(00)03409-7"},{"key":"ref=14","doi-asserted-by":"crossref","unstructured":"Cobb MN, Desai J, Brown LS jr. et al. The effect of\u00a0fluconazole on the clinical pharmacokinetics of\u00a0methadone. Clin Pharmacol Ther 1998; 63: 655\u201362.","DOI":"10.1016\/S0009-9236(98)90089-3"},{"key":"ref=15","doi-asserted-by":"crossref","unstructured":"Iribarne C, Picart D, Dreano Y et al. Involvement of\u00a0cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci 1997; 60: 1953\u201364.","DOI":"10.1016\/S0024-3205(97)00160-4"},{"key":"ref=16","unstructured":"Moody DE, Alburges ME, Parker RJ et al. The involvement of cytochrome P450 3A4 in the N-demethylation of L-alpha-acetylmethadol (LAAM), norLAAM, and methadone. Drug Metab Dispos 1997; 25: 1347\u201353."},{"key":"ref=17","doi-asserted-by":"crossref","unstructured":"Ray WA, Murray KT, Meredith S et al. Oral erythromycin and the risk of sudden death from cardiac causes. N Engl J Med 2004; 351: 1089\u201396.","DOI":"10.1056\/NEJMoa040582"},{"key":"ref=18","doi-asserted-by":"crossref","unstructured":"McCance-Katz EF. Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral agents. Clin Infect Dis 2005; 41 (suppl 1) 89\u201395.","DOI":"10.1086\/429503"},{"key":"ref=19","doi-asserted-by":"crossref","unstructured":"Lintzeris N, Mitchell TB, Bond A et al. Interactions on mixing diazepam with methadone or buprenorphine in maintenance patients. J Clin Psychopharmacol 2006; 26: 274\u201383.","DOI":"10.1097\/01.jcp.0000219050.33008.61"}],"container-title":["Tidsskrift for Den norske legeforening"],"original-title":[],"language":"no","deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T05:45:54Z","timestamp":1781675154000},"score":1,"resource":{"primary":{"URL":"https:\/\/tidsskriftet.no\/2009\/11\/legemidler-i-praksis\/interaksjoner-med-metadon-og-buprenorfin"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,19]]},"references-count":19,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2009,11,19]]}},"URL":"https:\/\/doi.org\/10.4045\/tidsskr.09.0471","relation":{},"ISSN":["0029-2001","0807-7096"],"issn-type":[{"value":"0029-2001","type":"print"},{"value":"0807-7096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,11,19]]}}}